HC Wainwright Analysts Decrease Earnings Estimates for MIST

Milestone Pharmaceuticals Inc. (NASDAQ:MIST - Free Report) - Equities research analysts at HC Wainwright decreased their Q1 2025 EPS estimates for shares of Milestone Pharmaceuticals in a research note issued on Monday, January 27th. HC Wainwright analyst P. Trucchio now expects that the company will earn ($0.17) per share for the quarter, down from their previous estimate of ($0.16). HC Wainwright currently has a "Buy" rating and a $25.00 target price on the stock. The consensus estimate for Milestone Pharmaceuticals' current full-year earnings is ($0.62) per share. HC Wainwright also issued estimates for Milestone Pharmaceuticals' Q2 2025 earnings at ($0.20) EPS, Q3 2025 earnings at ($0.32) EPS, Q4 2025 earnings at ($0.29) EPS, FY2025 earnings at ($0.99) EPS, FY2026 earnings at ($0.84) EPS, FY2027 earnings at $0.02 EPS and FY2028 earnings at $0.46 EPS.

Milestone Pharmaceuticals (NASDAQ:MIST - Get Free Report) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.14) earnings per share for the quarter, topping the consensus estimate of ($0.18) by $0.04.

Milestone Pharmaceuticals Price Performance

MIST stock traded down $0.05 during midday trading on Wednesday, reaching $1.97. 1,868,976 shares of the company's stock traded hands, compared to its average volume of 558,946. The company has a quick ratio of 15.40, a current ratio of 15.40 and a debt-to-equity ratio of 2.18. The company has a market cap of $105.06 million, a price-to-earnings ratio of -2.43 and a beta of 1.78. The company has a 50-day simple moving average of $1.98 and a two-hundred day simple moving average of $1.68. Milestone Pharmaceuticals has a 1-year low of $1.12 and a 1-year high of $2.75.

Institutional Trading of Milestone Pharmaceuticals

A number of hedge funds and other institutional investors have recently made changes to their positions in MIST. Valeo Financial Advisors LLC grew its holdings in Milestone Pharmaceuticals by 100.0% during the 3rd quarter. Valeo Financial Advisors LLC now owns 20,000 shares of the company's stock worth $30,000 after acquiring an additional 10,000 shares during the last quarter. Atria Investments Inc lifted its position in shares of Milestone Pharmaceuticals by 44.4% during the third quarter. Atria Investments Inc now owns 40,421 shares of the company's stock worth $61,000 after purchasing an additional 12,430 shares in the last quarter. BML Capital Management LLC grew its stake in shares of Milestone Pharmaceuticals by 3.0% during the third quarter. BML Capital Management LLC now owns 1,136,091 shares of the company's stock valued at $1,727,000 after purchasing an additional 33,196 shares during the last quarter. Finally, PVG Asset Management Corp acquired a new stake in shares of Milestone Pharmaceuticals in the third quarter valued at approximately $46,000. 86.18% of the stock is currently owned by institutional investors and hedge funds.

About Milestone Pharmaceuticals

Milestone Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate.